CPT code 82962 covers patient-performed blood glucose monitoring using small electronic, FDA-approved devices (the common “fingerstick” method). This code captures a widely used, high-frequency point-of-care service critical to diabetes self-management and preventive care. Nationally, home blood glucose testing influences ambulatory care workflows, supplies utilization, and short-term clinical decision making for patients with diabetes and related metabolic disorders.

Key payers in the national context include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of how 82962 is defined clinically and operationally, common payer coverage considerations, and where this service fits in routine outpatient and home care pathways. The publication summarizes benchmark themes such as utilization patterns, payer coverage scope, and billing considerations relevant to providers, coders, and policy analysts.

The report also provides clinical context for when patient self-testing is used, typical sites of service, and how 82962 interacts with broader diabetes management protocols. Data not available in the input will be identified explicitly in relevant sections.